Literature DB >> 647687

Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.

T Skovsgaard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 647687

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  49 in total

Review 1.  Active efflux mechanisms for antimicrobial resistance.

Authors:  S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 2.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Intracellular pH and the control of multidrug resistance.

Authors:  S Simon; D Roy; M Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

5.  Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil.

Authors:  A R Safa
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

6.  Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.

Authors:  A Zenebergh; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer.

Authors:  B K Chang; J A Gregory
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Positive correlation between decreased cellular uptake, NADPH-glutathione reductase activity and adriamycin resistance in Ehrlich ascites tumor lines.

Authors:  M E Scheulen; H Hoensch; H Kappus; S Seeber; C G Schmidt
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

10.  Initial and early effects of adriamycin in murine sarcoma 180 cannot be restored in a resistant subline by increasing the uptake and external concentration of the drug.

Authors:  J Sonka; U Schossig; M Vogt-Schaden; M Volm
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.